目錄:MedChemExpress LLC>>生化試劑>> VE-821 | MCE
CAS | 1232410-49-9 | 純度 | 98.32% |
---|---|---|---|
分子量 | 368.41 | 分子式 | C??H??N?O?S |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-14731 | 應用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務。
CAS No. : 1232410-49-9
產(chǎn)品活性:VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.
研究領(lǐng)域:Cell Cycle/DNA Damage | PI3K/Akt/mTOR
作用靶點:ATM/ATR
In Vitro: VE-821 shows excellent selectivity for ATR with minimal cross-reactivity against the related PIKKs ATM, DNA-PK, mTOR and PI3Kγ (Kis of 16 μM, 2.2 μM, >1 μM and 3.9 μM, respectively) and against a large panel of unrelated protein kinases. VE-821 (compound 27) also inhibits ATM and DNA-PK wirh IC50 of >8 μM, and 4.4 μM, respectively. VE-821 significantly enhances the sensitivity of PSN-1, MiaPaCa-2 and primary PancM pancreatic cancer cells to radiation and Gemcitabine under both normoxic and hypoxic conditions. ATR inhibition by VE-821 leads to inhibition of radiation-induced G2/M arrest in cancer cells. In both PSN-1 and MiaPaCa-2 cells, 1 µM VE-821 inhibits phosphorylation of Chk1 (Ser 345) after treatment with Gemcitabine (100 nM), radiation (6 Gy) or both, at 2 h post-irradiation.
相關(guān)產(chǎn)品:Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Chemical Probe Library | Anti-Pancreatic Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Glucose Metabolism Compound Library | Targeted Diversity Library | Cancer Stem Cells Compound Library | Tuvusertib | Elimusertib | CGK733 | AZD1390 | Ceralasertib | AZD-7648 | KU 59403 | KU-55933 | ATM Inhibitor-3 | Elimusertib-d3 | ATR-IN-6 | AZD0156 | CP-466722 | Antitumor agent-28 | ATR-IN-12 | ATR-IN-18 | ATR-IN-13 | ATR-IN-5 | ATR-IN-20 | AZ32 | ATM Inhibitor-2 | Ro 90-7501 | ATR-IN-17 | ATR-IN-4 | ATR-IN-11 | AZ31 | KU-60019 | ATR-IN-10
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應用于新藥研發(fā)、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術(shù)服務;
• 設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。